Evidence map›Paper›PMID 37936609›Full record

ArticleFrontiers in oncology2023

Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors.

Liqiong Xue, Wenbo Tang, Jiuli Zhou, Junli Xue, Qun Li, Xiaoxiao Ge, Fengjuan Lin, Wei Zhao, Ye Guo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma.Journal of experimental & clinical cancer research : CR · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Liqiong Xue *Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Wenbo Tang *Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Jiuli Zhou *Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Junli XueDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Qun LiDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Xiaoxiao GeDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Fengjuan LinDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Wei ZhaoDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Ye GuoDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Shanghai East Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study aimed to identify potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) and further probe the prognostic implications of CDKN2A mutations, particularly within a subset receiving immunotherapy. Methods: In this retrospective single-center study, we evaluated the next-generation sequencing (NGS) data from Foundation Medicine (FM) for patients with recurrent or metastatic HNSCC between January 1, 2019, and December 31, 2021. Patients were stratified based on CDKN2A loss-of-function (LOF) versus wild-type (WT) categorizations, with a focused subgroup analysis on those administered immunotherapy. Results: The study encompassed 77 patients, of which 62 had undergone immunotherapy. The median duration of follow-up was 22.6 months. For the CDKN2A LOF group, the median overall survival (OS) was 16.5 months, contrasted with 30.0 months in the CDKN2A WT group ( Conclusion: Alterations manifesting as LOF in the CDKN2A gene stand as robust indicators of unfavorable survival outcomes in HNSCC patients, including the subset that underwent immunotherapy.

Indexed as

cyclin-dependent kinase inhibitor 2Ahead and neck squamous cell carcinomaimmunotherapynext-generation sequencingprognosis

Identifiers

PMID37936609
PMCPMC10627168
OpenAlexW4387868969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.